CTRI/2022/11/047049招募中3 期
ANDROMEDA-SHOCK-2 TRIAL - A2
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion criteria
- •- Consecutive adult patients (= 18 years) with septic shock according to Sepsis-3 consensus conference. In short, septic shock is defined as suspected or confirmed infection, plus hyperlactatemia and NE requirements due to persistent hypotension, after a fluid load of at least 1000mL in 1h.
排除标准
- •Exclusion criteria
- •- More than 4 hours since septic shock diagnosis,
- •- Anticipated surgery or acute hemodialysis procedure to start during the
- •6h intervention period
- •- Active bleeding,
- •- Do not resuscitate status,
- •- Child B-C Cirrhosis
- •- Underlying disease process with a life expectancy < 90 days and/or the
- •attending clinician deems aggressive resuscitation unsuitable
- •- Refractory shock (high risk of death within 24h)
- •- Pregnancy
- •- Concomitant severe acute respiratory distress syndrome.
- •- Patients in whom CRT cannot be accurately assessed
研究者
相似试验
进行中（未招募）
1 期
/AEUCTR2011-002228-42-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
进行中（未招募）
不适用
A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE DOSE, 5-WAY CROSSOVER STUDY ASSESSING THE PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILES OF ORAL INHALED PF-03635659 IN PATIENTS WITH MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASEChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2009-014540-11-DEPfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK20
进行中（未招募）
1 期
The Attractive 2 trial – An open-label, randomised, 2-period cross-over trial to assess the pharmacokinetics of ATR-258 oral capsule vs. oral solution formulations in healthy volunteersCTIS2023-508797-28-00Atrogi AB12
进行中（未招募）
1 期
/APatients older than 15 years with hematologic or pulmonary lesions of telomeropathies.MedDRA version: 20.0 Level: PT Classification code 10062759 Term: Congenital dyskeratosis System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001686-17-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)40
进行中（未招募）
1 期
ot applicableinverse psoriasisEUCTR2015-002098-40-DEEO Pharma A/S